



(51) International Patent Classification:

C07K 16/32 (2006.01) A61P 35/00 (2006.01)
C07K 16/46 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2024/057935

(22) International Filing Date:

28 November 2024 (28.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/604,087 29 November 2023 (29.11.2023) US

(71) Applicant: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US).

(72) Inventors: RENSHAW, Blair; 16210 SE 166th Ct, Renton, Washington 98058 (US). ZHU, Yi; 15318 NE 95th St, Redmond, Washington 98052 (US).

(74) Agent: WAN, Feng; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BISPECIFIC TETRAVALENT ANTIBODY TARGETING HER2 AND HER3



(57) Abstract: Anti-HER2 X HER3 bispecific tetraivalent antibodies are configured to have two heavy chains and two light chains and two scFv domains linked to each heavy chain at the N-terminus through a linker, when the Fab region has a binding affinity to HER2 and the scFv domain has a binding affinity to HER3 or vice versa.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))